TransMedics Group, Inc. (TMDX)
NASDAQ: TMDX · Real-Time Price · USD
135.59
+5.78 (4.45%)
At close: Jun 5, 2025, 4:00 PM
135.70
+0.11 (0.08%)
After-hours: Jun 5, 2025, 4:31 PM EDT
TransMedics Group Stock Forecast
Stock Price Forecast
According to 9 professional analysts, the 12-month price target for TransMedics Group stock ranges from a low of $75 to a high of $178. The average analyst price target of $125.11 forecasts a -7.73% decrease in the stock price over the next year.
Price Target: $125.11 (-7.73%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for TransMedics Group stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
---|---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
Buy | 4 | 4 | 4 | 4 | 4 | 4 |
Hold | 4 | 4 | 3 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 11 | 11 | 10 | 10 | 10 | 10 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Piper Sandler | Piper Sandler | Buy Reiterates $125 → $145 | Buy | Reiterates | $125 → $145 | +6.94% | Jun 4, 2025 |
Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Jun 3, 2025 |
Oppenheimer | Oppenheimer | Buy Maintains $125 → $130 | Buy | Maintains | $125 → $130 | -4.12% | May 9, 2025 |
Piper Sandler | Piper Sandler | Buy Reiterates $105 → $125 | Buy | Reiterates | $105 → $125 | -7.81% | May 9, 2025 |
Piper Sandler | Piper Sandler | Buy Reiterates $90 → $105 | Buy | Reiterates | $90 → $105 | -22.56% | Apr 29, 2025 |
Financial Forecast
Revenue This Year
591.89M
from 441.54M
Increased by 34.05%
Revenue Next Year
710.35M
from 591.89M
Increased by 20.01%
EPS This Year
1.80
from 1.01
Increased by 77.93%
EPS Next Year
2.52
from 1.80
Increased by 40.47%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 614.8M | 769.3M | 928.3M | ||
Avg | 591.9M | 710.4M | 830.0M | ||
Low | 564.7M | 638.8M | 715.8M |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 39.2% | 30.0% | 30.7% | ||
Avg | 34.1% | 20.0% | 16.8% | ||
Low | 27.9% | 7.9% | 0.8% |
EPS Forecast
EPS | 2025 | 2026 | 2027 |
---|---|---|---|
High | 2.03 | 3.10 | 4.17 |
Avg | 1.80 | 2.52 | 3.17 |
Low | 1.28 | 1.95 | 2.09 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 |
---|---|---|---|
High | 100.6% | 72.4% | 65.1% |
Avg | 77.9% | 40.5% | 25.4% |
Low | 27.1% | 8.5% | -17.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.